Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
How do you counsel and manage joint pain after isotretinoin treatment?
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?